Zoetis Inc (NYSE:ZTS) EVP Kristin C. Peck sold 11,500 shares of the stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $123.22, for a total value of $1,417,030.00. Following the completion of the transaction, the executive vice president now directly owns 48,877 shares of the company’s stock, valued at $6,022,623.94. The sale was disclosed in a filing with the SEC, which is available through this link.
Shares of NYSE:ZTS traded down $2.91 on Wednesday, reaching $121.79. 1,875,196 shares of the company traded hands, compared to its average volume of 2,154,767. Zoetis Inc has a fifty-two week low of $78.90 and a fifty-two week high of $125.88. The firm has a 50 day simple moving average of $115.93. The stock has a market cap of $59.87 billion, a PE ratio of 39.05, a PEG ratio of 3.16 and a beta of 0.92. The company has a debt-to-equity ratio of 2.74, a current ratio of 4.17 and a quick ratio of 2.87.
Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $0.90 EPS for the quarter, beating analysts’ consensus estimates of $0.82 by $0.08. Zoetis had a return on equity of 72.86% and a net margin of 22.74%. The company had revenue of $1.55 billion during the quarter, compared to the consensus estimate of $1.51 billion. During the same quarter in the prior year, the firm earned $0.77 EPS. The company’s quarterly revenue was up 9.3% compared to the same quarter last year. As a group, research analysts forecast that Zoetis Inc will post 3.57 earnings per share for the current fiscal year.
Several large investors have recently made changes to their positions in ZTS. FMR LLC lifted its position in shares of Zoetis by 12.2% during the 1st quarter. FMR LLC now owns 8,127,931 shares of the company’s stock valued at $818,239,000 after acquiring an additional 882,183 shares during the last quarter. BlackRock Inc. lifted its position in shares of Zoetis by 2.2% during the 1st quarter. BlackRock Inc. now owns 37,486,408 shares of the company’s stock valued at $3,773,759,000 after acquiring an additional 795,558 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Zoetis by 14.4% during the 4th quarter. Geode Capital Management LLC now owns 6,227,976 shares of the company’s stock valued at $531,801,000 after acquiring an additional 785,088 shares during the last quarter. American Century Companies Inc. lifted its position in shares of Zoetis by 12.8% during the 1st quarter. American Century Companies Inc. now owns 4,539,546 shares of the company’s stock valued at $456,996,000 after acquiring an additional 513,924 shares during the last quarter. Finally, Close Asset Management Ltd acquired a new stake in shares of Zoetis during the 1st quarter valued at $47,140,000. Institutional investors own 90.08% of the company’s stock.
A number of equities analysts recently issued reports on the company. Stifel Nicolaus increased their price objective on Zoetis from $110.00 to $130.00 and gave the stock a “buy” rating in a report on Monday, July 22nd. Zacks Investment Research lowered Zoetis from a “buy” rating to a “hold” rating in a research note on Monday, May 6th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $130.00 price target (up from $116.00) on shares of Zoetis in a research note on Wednesday, June 12th. Guggenheim assumed coverage on Zoetis in a research note on Thursday, May 23rd. They set a “buy” rating and a $114.00 price target for the company. Finally, Gabelli lowered Zoetis from a “buy” rating to a “hold” rating and set a $108.00 price target for the company. in a research note on Thursday, May 2nd. They noted that the move was a valuation call. Seven analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $115.13.
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Featured Article: Understanding Options Trading
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.